| Date Filed | Type | Description |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/04/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
8-K/A
| Cost Associated with Exit or Disposal Activities Interactive Data |
| 06/05/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 05/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/08/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
SC 13G/A
| BlackRock Inc. reports a 10.9% stake in TWIST BIOSCIENCE CORP |
| 03/28/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G/A
| ARK Investment Management LLC reports a 11.8% stake in Twist Bioscience Corporation |
| 02/10/2023 |
SC 13G
| Nikko Asset Management Americas, Inc. reports a 5.2% stake in Twist Bioscience Corporation |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 5.5% stake in TWIST BIOSCIENCE CORP |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.2% stake in Twist Bioscience Corp. |
| 02/08/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
8-K
| Quarterly results |
| 01/13/2023 |
SC 13G
| JPMORGAN CHASE & CO reports a 6.7% stake in Twist Bioscience Corporation |
| 01/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/12/2022 |
SC 13G/A
| FMR LLC reports a 5.6% stake in TWIST BIOSCIENCE CORP |
| 11/28/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/28/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 11/18/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 11/18/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 10/26/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/05/2022 |
8-K
| Quarterly results |
| 06/09/2022 |
SC 13G/A
| ARK Investment Management LLC reports a 11.1% stake in Twist Bioscience Corporation |
| 05/06/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
8-K
| Quarterly results |
| 04/22/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Twist Bioscience Announces Promotions and Changes to Executive Leadership Team SOUTH SAN FRANCISCO, CA – April 21, 2022 — Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development. In addition, Patrick Weiss will step down from his role as chief operating officer into a strategic advisor role for personal reasons, effective April 21, 2022, while a formal search is conducted for his replacement. “Tracey joined Twist through the acquisition of Abveris and quickly demonstrated her capability to lead dynamic organizations,” said Emi..." |
|
| 03/10/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|